The Assessment of Molecular Breast Imaging (MBI) in Distinguishing Benign From Malignant Breast Disease
The Assessment of Molecular Breast Imaging (MBI) in Distinguishing Benign From Malignant Breast Disease
The primary hypothesis of this project is that using molecular breast imaging (MBI) in
 evaluating women with equivocal mammographic or sonographic findings will demonstrate high
 specificity in distinguishing benign from malignant breast disease and, as a result, decrease
 the number of biopsies.
Inclusion Criteria:

 -  18 years of age or older

 -  Women who have indeterminate mammographic or sonographic findings who are recommended
 and for biopsy

 Exclusion Criteria:

 -  Known contraindication to mammographic imaging

 -  women who are pregnant

 -  women who are lactating

 -  women who have significant existing breast trauma

 -  women who have breast implants

 -  Women under 18 years of age.

 -  women who had previous benign breast surgery within 1 year

 -  Males and children

 -  Women who are unable to understand or execute written informed consent

 -  Women who refuse to have a biopsy

 -  Women with any known renal disease - if an MRI is deemed necessary, a serum creatine
 will be checked prior to injection of contrast. Using the National Kidney Foundation
 recommendations, a glomerular filtration rate (GFR) greater than 60 may safely receive
 intravenous gadolinium-based MRI contrast. Those individuals with a GFR >30 and <60
 can receive the contrast but at a reduced dose (typically half). Those with a GFR <30
 will not receive MRI contrast and will not undergo the exam. Breast MRI must be done
 with contrast if evaluating for cancer. Several factors can affect the GFR such as
 age, body size, creatinine, renal status and will be calculated from the blood drawn.
 GFR is the final determinant and a creatinine greater than 1.6 usually has a GFR that
 precludes a Breast MRI with contrast. The final determinant will be the GFR.